Sanofi Collaboration Indapta has a clinical study collaboration with Sanofi on a multiple myeloma program, signaling validation of their g-NK platform and providing a blueprint for future co-development or licensing deals with a major pharma partner in hematologic cancers and NK cell therapies.

Funding Momentum The company has secured significant funding rounds, including a recent Series A and additional venture investment, alongside FDA Fast Track designation for lead candidate IDP-023. This combination indicates strong financial runway, regulatory momentum, and a favorable environment for milestone-driven partnerships and co-investments.

ADCC Advantage Indapta's allogeneic g-NK cells exhibit potent antibody-dependent cellular cytotoxicity and enhanced synapse formation, enabling potent combinations with IgG1 monoclonal antibodies, ADCs, or innate immune cell engagers—creating multiple partnership angles with antibody and bi- or tri-specific platform developers.

IDP-023 Spotlight Lead program IDP-023 targets non-Hodgkin's lymphoma and multiple myeloma, with clinical progression and regulatory support. The combination potential and early data offer opportunities to co-develop or license the asset with hematology-oncology portfolios and to expand into additional indications with partner programs.

Operational Agility As a small, nimble company with a footprint in Houston and Seattle and a data-driven TIMING platform, Indapta can move quickly to establish manufacturing and development partnerships, CRO/CMO collaborations, or technology licensing of their NK cell platform to accelerate clinical timelines for partners.